Search clinical trials for: BI 695500

Total 1234 results

Boehringer Ingelheim

Terminated

Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis

Arthritis, Rheumatoid

United States, Belgium, Bulgaria, Germany, Greece, Netherlands, Poland, Portugal, Spain
Boehringer Ingelheim

Completed

Assessment of the Handling Experience With the BI 695501 Autoinjector in Patients With Rheumatoid Arthritis Followed by an Extension Phase Using BI 695501 Prefilled Syringe

Arthritis, Rheumatoid

United States, Poland
Boehringer Ingelheim

Completed

Pharmacokinetics and Safety of BI 695501 Administered Via Prefilled Syringe or Autoinjector

Healthy

Belgium
Boehringer Ingelheim

Completed

A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Diabetic Kidney Disease

Diabetic Nephropathies

Spain, Australia, United States, Canada, China, Japan, Malaysia, United Kingdom, Mexico, Portugal, Denmark, Hong Kong, Poland, New Zealand, Argentina, Netherlands
Boehringer Ingelheim

Completed

A Study in Healthy People to Test How 2 Different Formulations of BI 695501 Are Taken up by the Body When Given as an Injection

Healthy

United States
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 685509 is Processed in the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

This Study Tests BI 685509 in Healthy Chinese and Japanese Men; the Study Tests How Different Doses of BI 685509 Are Taken up in the Body and How Well They Are Tolerated

Healthy

Korea, Republic of, Japan
Boehringer Ingelheim

Completed

Investigation of Single Rising Doses of BI 685509

Healthy

Germany
Boehringer Ingelheim

Completed

A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Chronic Kidney Disease

Chronic Kidney Disease

Spain, Canada, Australia, United States, Japan, Malaysia, United Kingdom, China, Mexico, Denmark, Russian Federation, Germany, Portugal, Hong Kong, Poland, Argentina, New Zealand, Sweden
Boehringer Ingelheim

Completed

This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses)

Diabetic Nephropathies

United States, Canada, Belgium, Czechia, Germany
Boehringer Ingelheim

Completed

Safety and Tolerability of BI 685509 in Healthy Subjects

Healthy

Germany
Boehringer Ingelheim

Active, not recruiting

A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Live

Hypertension, Portal

Spain, Denmark, United Kingdom, Singapore, Germany, Italy, Austria, Canada, Croatia, China, Taiwan, Netherlands, Belgium, United States, Korea, Republic of, Japan, Argentina, France, Switzerland, Portugal, Israel, Romania
Boehringer Ingelheim

Recruiting

A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms (VITALISScE™)

Scleroderma, Systemic

United States, Belgium, Korea, Republic of, Australia, China, Taiwan, Spain, Israel, Japan, Mexico, Turkey, Germany, Italy, Brazil, France, Singapore, Canada, Philippines, United Kingdom, Finland, Greece, New Zealand, Denmark, Malaysia, Indi... and more
Boehringer Ingelheim

Completed

Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis

Arthritis, Rheumatoid

United States, Spain, Korea, Republic of, Thailand, Malaysia, Poland, Russian Federation, Serbia, Bulgaria, Chile, Estonia, Germany, Hungary, Ukraine
Boehringer Ingelheim

Recruiting

A Study to Test How Avenciguat (BI 685509) is Taken up in the Body of People With and Without Liver Problems

Liver Diseases | Healthy

United States
Boehringer Ingelheim

Completed

A Study to Test How Different Doses of BI 685509 Are Tolerated in Patients With Liver Problems

Hepatic Insufficiency | Healthy

United States
Boehringer Ingelheim

Recruiting

A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly

Liver Cirrhosis | Hypertension, Portal

Germany, Spain, Japan, China, United States, Korea, Republic of, Canada, France, Austria, Romania
Boehringer Ingelheim

Completed

BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity

Crohn Disease

Serbia, United Kingdom, United States, Czechia, Germany, Greece, Poland, Russian Federation, Turkey, Israel, Belarus, Ukraine, Croatia, Bosnia and Herzegovina
Boehringer Ingelheim

Completed

Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis

United States, Germany, Russian Federation, Czechia, Poland, Ukraine, Estonia, Slovakia
Boehringer Ingelheim

Terminated

BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma

Lymphoma, Non-Hodgkin

Austria, Belgium, United States, Bulgaria, Croatia, Czech Republic
Boehringer Ingelheim

Completed

The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira® and BI 695501 in Patients With Plaque Psoriasis

Psoriasis

United States, Poland, Hungary, Germany, Latvia, Russian Federation, Ukraine
Boehringer Ingelheim

Completed

BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis

Arthritis, Rheumatoid

Spain, United States, Korea, Republic of, Malaysia, Poland, Thailand, Bulgaria, Chile, Estonia, Germany, Hungary, New Zealand, Russian Federation, Serbia, Ukraine
Boehringer Ingelheim

Completed

Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma

Lymphoma, Follicular

Spain, Belgium, Czechia, France, Croatia, Germany, Austria, New Zealand, Australia, Greece, Hungary, Poland, Russian Federation
Boehringer Ingelheim

Completed

Pharmacokinetics and Safety in Healthy Volunteers

Healthy

Belgium, New Zealand
Marinus Pharmaceuticals

Completed

Open-label Extension to Protocol 1042-0600

Epilepsies, Partial

United States
Boehringer Ingelheim

Terminated

Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis

Arthritis, Rheumatoid

United States, United Kingdom, Netherlands, Ireland, Argentina, Poland, Mexico, Spain, Bulgaria, Chile, Germany, Ukraine, Portugal, Belgium, Canada, Greece, Hungary
Boehringer Ingelheim

Completed

A Study in Healthy People to Compare Two Different Tablets of BI 685509 and to Test How Food and Esomeprazole Influence the Amount of BI 685509 in the Blood

Healthy

Germany
Children's Hospital Zagreb
GuardianMed j.d.o.o. Research and development in medicine

Withdrawn

Antiseptic-coated Intermittent Urinary Catheter (GuardianCath)

Catheter-Related Infections | Neurogenic Bladder

Croatia
Boehringer Ingelheim

Completed

Open-label, Single Arm Trial of BI 695502 in Patients With Previously Untreated Metastatic Colorectal Cancer (INVICTAN®-3)

Colorectal Neoplasms

United States, Spain, Ukraine, Japan
Boehringer Ingelheim

Completed

Pharmacokinetics and Safety Study of BI 695502 in Healthy Subjects

Healthy

New Zealand
Boehringer Ingelheim

Completed

Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer

Carcinoma, Non-Small-Cell Lung

Spain, Bulgaria, Serbia, United Kingdom, United States, Korea, Republic of, Malaysia, Vietnam, Poland, Egypt, Hungary, Ukraine, Brazil, Turkey, Japan, Portugal, Thailand, Philippines, Russian Federation, Italy, Mexico, Greece, Croatia, Chi... and more
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test if Taking Different Formulations of BI 1358894 With or Without Food Influences the Amount of BI 1358894 in the Blood

Healthy

Germany
Boehringer Ingelheim

Recruiting

A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab

Melanoma | Non-small Cell Lung Cancer (NSCLC) | Carcinoma, Squamous Cell of Head and Neck (HNSCC)

Netherlands
Boehringer Ingelheim

Not yet recruiting

A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity

Obesity
Boehringer Ingelheim

Completed

This Study in Healthy Men Tests How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Looks at How Food Influences the Amount of BI 1358894 in the Blood

Healthy

Germany
Boehringer Ingelheim

Withdrawn

A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer

Anal Canal Squamous Cell Carcinoma

Korea, Republic of
SIGA Technologies
United States Department of Defense

Completed

Study to Assess the Safety and Pharmacokinetics of TPOXX® When Administered Orally for 28 Days

Smallpox

United States
Boehringer Ingelheim

Recruiting

A Study in People With Advanced Cancer to Test How BI 907828 is Processed in the Body

Solid Tumors

Hungary
Boehringer Ingelheim

Terminated

A Study in Healthy Men to Find the Best Formulation of BI 894416 and to Test How This is Taken up in the Body

Healthy

United Kingdom
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics of Single Rising Oral Doses of BI 1181181 in Healthy Male Volunteers, Including Investigation of the Effect of Food on the Bioavailability of BI 1181181

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 1015550 is Taken up and Handled by the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1021958 in Otherwise Healthy Controlled Asthmatic Subjects

Healthy | Asthma

Germany
Boehringer Ingelheim

Completed

Single Rising Dose Study With Intravenous Infusion and Subcutaneous Injection of BI 1005273 in Healthy Male Volunteers.

Healthy

Germany
Boehringer Ingelheim

Completed

This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.

Neoplasms | Carcinoma, Non-Small-Cell Lung

United States, Spain, United Kingdom, Canada, Poland
Boehringer Ingelheim

Terminated

A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread

Neoplasms | Carcinoma, Non-Small-Cell Lung | Neoplasm Metastasis

United States
Boehringer Ingelheim

Completed

A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS])

Solid Tumors, KRAS Mutation

Japan
Boehringer Ingelheim

Completed

A Study to Test Different Doses of BI 765063 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer (Solid Tumors)

Solid Tumors

Japan
Boehringer Ingelheim

Completed

A Study in Healthy Men to Measure the Amount of BI 730357 in the Blood When Taken as a Tablet

Healthy

Netherlands
Boehringer Ingelheim

Completed

Multiple Rising Oral Doses of BI 1060469 in Healthy Subjects and Mild Asthma Patients

Asthma

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test if Different Formulations of BI 764198 With or Without Food Influence the Amount of BI 764198 in the Blood

Healthy

Belgium

3

Subscribe